TORNTPHARM: Revenue rose 51%, but PAT fell as merger integration weighed on JB business
阅读少于1分钟
Q2 FY27 revenue rose 51% YoY to Rs 4,979 crore and operating EBITDA grew 54%, while PAT fell 9.6%. Base business grew 18%; JB integration and German supply issues weighed on select operations.
Original document: Torrent Pharmaceuticals Ltd [TORNTPHARM] Interim report — Oct. 23 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr